Life AI Net
ホーム
アーカイブ
計算ツール
ディレクトリ
ニュースレター
ログイン
日本語
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
ホーム
アーカイブ
計算ツール
ディレクトリ
ニュースレター
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
ログイン
ホーム
アーカイブ
計算ツール
ディレクトリ
More
ライブ
Thermo Fisher
How Investors Are Reacting To Thermo Fisher Scientific (TMO) Expanding Its U.S. Bioprocess Design Center - Yahoo Finance
Illumina
Illumina Reports Financial Results for First Quarter of Fiscal Year 2026 - PR Newswire
Science
Deepfakes are everywhere. The godfather of digital forensics is fighting back
Endpoints News
FDA's oncology advisors vote against 'new paradigm' in AstraZeneca trial
Endpoints News
Krazati fails confirmatory trial in colorectal cancer, putting approval at risk
10x Genomics Blog
Why 10x Genomics Stock Is Surging Today - TipRanks
FierceBiotech
AstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal
Endpoints News
House panel calls to ban China trial data from FDA drug trial applications
Endpoints News
Court dismisses part of Lilly lawsuit against Empower, some claims can proceed
Endpoints News
Supreme Court questions how far generics makers can go with 'skinny label' drugs
Illumina
Tempus AI vs. Illumina: Which Oncology Stock Is Worth Buying Now? - TradingView
MACHEREY-NAGEL GmbH & Co. KG
World Laboratory Filter Paper - Market Analysis, Forecast, Size, Trends and Insights - IndexBox
Thermo Fisher
How Investors Are Reacting To Thermo Fisher Scientific (TMO) Expanding Its U.S. Bioprocess Design Center - Yahoo Finance
Illumina
Illumina Reports Financial Results for First Quarter of Fiscal Year 2026 - PR Newswire
Science
Deepfakes are everywhere. The godfather of digital forensics is fighting back
Endpoints News
FDA's oncology advisors vote against 'new paradigm' in AstraZeneca trial
Endpoints News
Krazati fails confirmatory trial in colorectal cancer, putting approval at risk
10x Genomics Blog
Why 10x Genomics Stock Is Surging Today - TipRanks
FierceBiotech
AstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal
Endpoints News
House panel calls to ban China trial data from FDA drug trial applications
Endpoints News
Court dismisses part of Lilly lawsuit against Empower, some claims can proceed
Endpoints News
Supreme Court questions how far generics makers can go with 'skinny label' drugs
Illumina
Tempus AI vs. Illumina: Which Oncology Stock Is Worth Buying Now? - TradingView
MACHEREY-NAGEL GmbH & Co. KG
World Laboratory Filter Paper - Market Analysis, Forecast, Size, Trends and Insights - IndexBox
アーカイブ
BioWorld
2026年4月30日
Other news to note for April 30, 2026
Other news to note for April 30, 2026
原文
本文は利用できません。元の情報源をご確認ください。